Stocks · News reference
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(3.47) by 29.68 percent. This is a 17.57 percent increase over losses of $(2.96) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Law firms are investigating the proposed merger between Passage Bio, Inc. and Remix Therapeutics, Inc. to determine if the transaction provides fair value to shareholders.
Class action law firm Monteverde & Associates PC is investigating four major merger and acquisition transactions to determine if shareholders are receiving fair deal terms. The investigations involve Utz Brands' sale to Intersnack Group, Safety Insurance Group's sale to Mapfre affiliate, Passage Bio's merger with Remix Therapeutics, and Finward Bancorp's sale to First Financial Bancorp.
Filed: 2026-09-03 AccNo: 0001140361-26-035515 Size: 3 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits